Secondly, the molecular mechanisms of PLCG2 in CRC and TME, especially the modulation of immune checkpoints and CD8+ T cells, require in-depth explorations to clarify the crucial role of PLCG2 and to discover more therapeutic targets, which is also the focus of our subsequent research. This evidence concerns the gene CD8A and colorectal carcinoma.